Antidepressant medications, neuroleptics, and prominent eye movements during NREM sleep

Journal of Clinical Neurophysiology

Volumn 26, Issue 1, 2009, Pages 39-44

  Geyer, James D ^a   Carney, Paul R ^b   Dillard, Stephenie C ^a   Davis, Lori ^c,d   Ward, Leo C ^c  

^a UNIVERSITY OF ALABAMA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Depression; NREM sleep eye movements; Polysomnography

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLONAZEPAM; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PROTRIPTYLINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; VENLAFAXINE; ZOLPIDEM; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; MIANSERIN; PYRIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; AGED; AROUSAL; ARTICLE; DRUG USE; EYE MOVEMENT; EYE MOVEMENT DISORDER; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONREM SLEEP; POLYSOMNOGRAPHY; TREATMENT WITHDRAWAL; DRUG EFFECT; MIDDLE AGED; OCULOGRAPHY; PHYSIOLOGY; SLEEP STAGE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLONAZEPAM; EYE MOVEMENT MEASUREMENTS; EYE MOVEMENTS; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; POLYSOMNOGRAPHY; PYRIDINES; SEROTONIN UPTAKE INHIBITORS; SLEEP STAGES; YOUNG ADULT;

EID: 65549157478     PISSN: 07360258     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNP.0b013e318196046f     Document Type: Article

References (16)

1. Armitage R, Trivedi M, Rush AJ. Fluoxetine and oculomotor activity during sleep in depressed patients. Neuropsychopharmacology. 1995;12:159-165.
2. BaHammam A. Comparison of nasal prong pressure and thermistor measurements for detecting respiratory events during sleep. Respiration. 2004;71:385-390.
3. Bonnet M, et al. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep. 1992;15:173-184.
4. Davis LL, Jewell ME, Ambrose S, et al. Nefazodone for posttraumatic stress disorder: a placebo-controlled trial. J Clinical Psychopharmacol. 2004;24:3:291-297.
5. Davis R, Wilder MI. Mirtazapine:a review of its pharmacology and therapeutic potential in management of major depression. CNS Drugs. 1996;5:389-402. (Pubitemid 126444387)
6. De Boer. The pharmacologic profile of mirtazapine. J Clin Psychiatr. 1996;57(suppl 4):19-23.
7. Haddjeri N, Blier P, de Montigny C. Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedebergs Arch Pharmacol. 1997;355:1:20-29. (Pubitemid 27008448)
8. Hamner MB, Robert S. Emerging roles for atypical antipsychotics in chronic post-traumatic stressdisorder. Expert Rev Neurother. 2005;5:2:267-275. (Pubitemid 40445148)
9. Jindal RD, Friedman ES, Berman SR, et al. Effects of sertraline on sleep architecture in patients with depression. Clin Psychopharmacol. 2003;23:540-548. (Pubitemid 37443184)
10. Kupfer DJ, Ehlers CL, Pollock BG, et al. Clomipramine and EEG sleep in depression. Psychiatry Res. 1989;30:165-180.
11. Rechtschaffen A, Kales AA. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Bethesda: National Institute of Neurological Diseases and Blindness, 1968.
12. Schenck CH, Mahowald MW, Kim SW, et al. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep. 1992;15:226-235.
13. Slembach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.
14. Stahl SM. Psychopharmacology of Antidepressants. London: Martin Dunitz, Ltd, 1997;71-79.
15. Taska L, Kupfer D. A system for the quantification of phasic ocular activity during REM sleep. Sleep Watchers. 1983;6:15-17.
16. Tychsen L, Sitaram N. Catecholamine depletion produces irrepressible saccadic eye movements in normal humans. Ann Neurol. 1989;25:444-449. (Pubitemid 19136674)